SPECCRO

Why SPECCRO? Pharma R&D has entered an era of diminishing returns—despite massive investments, nearly 90% of drug candidates still fail in clinical trials, often due to poor efficacy or undetected toxicity. Animal models, long the standard in preclinical testing, fall short in mimicking human biology. In a pivotal shift, the FDA has begun phasing out mandatory animal testing, opening the door to modern, human-relevant science. What SPECCRO Offers SPECCRO Inc. is the first specialized CRO built entirely around New Approach Methodologies (NAMs)—non-animal, technology-driven solutions for preclinical efficacy and safety assessment. Designed to bridge the “Valley of Death” in translational science, SPECCRO delivers robust, human-centric in vitro datasets that improve predictivity and accelerate clinical success. How We Deliver Our platform integrates advanced in vitro models with AI/ML-driven analytics, guided by seasoned scientific expertise. By translating complex data into actionable insights—through strategic technology partnerships and evidence-based interpretation—SPECCRO enables faster, more cost-effective development of safe, effective therapies. Who We Are SPECCRO is backed by a world-class scientific advisory team with over 200 years of combined experience in drug development, regulatory strategy, and translational science. We are building the future of preclinical research: human-relevant, scalable, ethical—and ready to lead.